Please use this identifier to cite or link to this item:
|Title:||A short report on highlights of worldwide development of RIX4414: A Singaporean experience|
De, Vos B.
|Keywords:||Attenuated human rotavirus vaccine|
Phase II clinical trial
|Citation:||Phua, K.B., Quak, S.H., Emmanuel, S., Goh, P.S.C., Han, H.H., Bock, H.L., Hardt, K., De, Vos B. (2006). A short report on highlights of worldwide development of RIX4414: A Singaporean experience. Vaccine 24 (18) : 3782-3783. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2006.03.040|
|Abstract:||In Singapore, we conducted a phase II randomized, double-blind, placebo-controlled dose ranging study using an attenuated human rotavirus vaccine, RIX4414. Altogether, 2464 healthy infants were recruited. Two oral doses of vaccine at 104.7, 105.2 or 106.1 ffu or placebo were administered with routine immunizations at 3 and 4 months of age. Seroconversion and 'vaccine take' in the vaccine groups 1-month post dose 2 varied from 76 to 91% and 98 to 100% respectively. Vaccine was well tolerated and did not interfere with response of concomitantly administered vaccines. © 2006 Elsevier Ltd. All rights reserved.|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 20, 2019
WEB OF SCIENCETM
checked on Mar 11, 2019
checked on Mar 17, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.